Verizon Communications (TG:BACL)
Historical Stock Chart
From Jul 2019 to Jul 2024
Bioaccelerate Holdings Inc. Announces Sponsorship of Milken
Institute Global Conference
NEW YORK, Feb. 16 /PRNewswire-FirstCall/ -- Bioaccelerate Holdings Inc.
(BACL.OB), a company that acquires and invests in the development of
pharmaceutical compounds, announced today its sponsorship of the annual Milken
Institute Global Conference, taking place April 18-April 20, 2005 at the
Beverly Hilton Hotel in Los Angeles, CA. The conference draws together more
than 2,000 senior decision makers from industry, government, financial
institutions, and philanthropy from over 50 countries to discuss and debate
ideas about how to solve some of the world's most pressing challenges.
"Bioaccelerate is delighted to be a major sponsor of this important annual
event for the second year in a row," stated Frank Armstrong, M.D., Chief
Operating Officer of Bioaccelerate. "Among the topics to be discussed at this
year's conference will be university-based biotechnology research, development
and commercialization. In a panel discussion to be led by Bioaccelerate,
prominent experts from academia and the pharmaceutical industry will explore
ways to help facilitate more efficient technology transfer so that promising
new medicines can be brought to market more quickly and cost effectively."
This year's conference, "Building a Prosperous Future," will examine such
issues as biotechnology and the promise of medical breakthroughs; the global
investment climate; and the latest economic developments in Europe, Asia,
Russia, Latin America and the U.S.
Among confirmed speakers at the conference are former Vice President Al Gore;
Rupert Murdoch, Chairman and CEO, News Corporation; Terry Semel, Chairman and
CEO, Yahoo!; Charlene Barshefsky, former U.S. Trade Representative; Mel
Karmazin, CEO, SIRIUS Satellite Radio; Steve Forbes, President and CEO, Forbes;
William Haseltine, former CEO, Human Genome Sciences; Douglas Holtz-Eakin,
Director, Congressional Budget Office; Jonathan Miller, Chairman and CEO, AOL;
Mike Milken, Chairman of FasterCures and the Milken Institute; Steve Wynn,
President and CEO, Wynn Resorts; Sam Zell, Chairman, Equity Group Investments;
and more than 200 others.
For complete information about the 2005 Global Conference, go to:
http://www.milkeninstitute.org/gc2005.
About Bioaccelerate Holdings Inc.
Bioaccelerate Holdings Inc. is a pharmaceutical development organization that
seeks to acquire, develop and commercialize novel pharmaceutical compounds in
an efficient, cost-effective way for the benefit patients and its shareholders.
Bioaccelerate uses its broad network of academic, industry and capital market
relationships to expedite drug development and raise capital to create and fund
its subsidiary companies, which are organized by vertical portfolios in five
therapeutic areas: oncology, specialty pharmaceuticals, central nervous system
disorders (CNS), cardiovascular disease and anti-infectives.
Bioaccelerate conducts its business directly and through its subsidiaries. The
company holds majority equity interests in ten biopharmaceutical companies
(three of which are public) and holds minority interests in four
biopharmaceutical companies (two of which are public). The company also holds
a minority equity interest in a public nanotechnology company.
Bioaccelerate's strategy relies on its development network for research,
clinical development and project management to guide early-stage compounds from
the discovery process through to Phase II/III development where incremental
value can be created. Bioaccelerate Holdings is quoted on the Over-The-Counter
Bulletin Board under the symbol "BACL.OB." For more information on
Bioaccelerate, visit the company's website at http://www.bioaccelerate.com/.
Bioaccelerate Safe Harbor Statement
Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements
include, but are not limited to: risks associated with pre-clinical and
clinical developments in the biopharmaceutical industry in general and in
Bioaccelerate's compounds under development in particular; the potential
failure of Bioaccelerate's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the early stage
of Bioaccelerate's compounds under development; failure to successfully
implement or complete clinical trials; failure to receive marketing clearance
from regulatory agencies for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic initiatives that change
Bioaccelerate's business, structure or projections; the development of
competing products; uncertainties related to Bioaccelerate's dependence on
third parties and partners. Bioaccelerate disclaims any obligation to update
these forward-looking statements.
About the Milken Institute
The Milken Institute is a nonprofit, independent economic think tank whose
mission is to improve the lives and economic conditions of diverse populations
around the world by helping business and public policy leaders identify and
implement innovative ideas for creating broad-based prosperity. It is based in
Santa Monica, CA. (http://www.milkeninstitute.org/)
Contact:
Bioaccelerate Holdings Inc.
Christopher O'Toole
Senior Vice President
212-897-6849
Matthew Haines (Investors)
Vice President
Noonan Russo
212-845-4235
Emily Poe (Media)
Vice President
Noonan Russo
212-845-4266
DATASOURCE: Bioaccelerate Holdings Inc.
CONTACT: Christopher O'Toole, Senior Vice President of Bioaccelerate
Holdings Inc., +1-212-897-6849; or Matthew Haines (Investors), Vice President,
+1-212-845-4235, or Emily Poe (Media), Vice President, +1-212-845-4266, both
of Noonan Russo, for Bioaccelerate Holdings Inc.
Web site: http://www.bioaccelerate.com/
http://www.milkeninstitute.org/
http://www.milkeninstitute.org/gc2005